Paprocki 1976.
| Methods | Randomisation: “administered at random”. Blinding: double‐blind. Duration: 90 days. Design: parallel. Location: State hospital “Instituto Raul Soares”, Belo Horizonte, Brasil. Setting: inpatients. |
|
| Participants | Diagnosis: acute schizophrenia. N = 50. Gender: 50F. Age: not indicated. History: duration stable: not indicated, duration of illness: not indicated, number of previous hospitalisations: not indicated, age at onset: not indicated, severity of illness: not indicated, baseline antipsychotic dose: not indicated. |
|
| Interventions | 1. Haloperidol: fixed/flexible dose: not indicated, dose range: not indicated, mean dose: not indicated. N = 25. 2. Loxapine: fixed/flexible dose: not indicated, dose range: not indicated, mean dose: not indicated. N = 25. |
|
| Outcomes | Unable to use: Global state general: Clinical Global Impression (CGI) (no raw data available). Mental state general: Brief Psychiatric Rating Scale (BPRS) (no raw data available). Behaviour: Nurses´ Observation scale for Inpatient Evaluation (NOSIE) (no raw data available). Adverse effects: Treatment Emergent Symptoms Scale (TESS) (no raw data available). |
|
| Notes | Study participants were 50 “acute newly hospitalized” female schizophrenic participants. "overall study of data obtained from three different trials." |
|
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | “Administered at random”. No further details. |
| Allocation concealment (selection bias) | Unclear risk | No further details. |
| Blinding (performance bias and detection bias) (performance bias) | Unclear risk | “Double‐blind”. No further details. |
| Blinding (performance bias and detection bias) (detection bias) | Unclear risk | “Double‐blind”. No further details. |
| Incomplete outcome data (attrition bias) All outcomes | Unclear risk | The study did not address this outcome; insufficient information to permit judgment concerning incomplete outcome data. |
| Selective reporting (reporting bias) | High risk | Outcome data were not fully addressed (no raw data for the BPRS, CGI, NOSIE, and TESS). Adverse effects reporting was incomplete. |
| Other bias | Unclear risk | Insufficient information to assess whether an important risk of bias exists. |